Cancer Theranostics: An Emerging Field for Cancer Research, Diagnosis and Therapy
Issue: 2022 - Volume 5 [Issue 2]
Ikalo David Oseghale *
Department of Biochemistry, University of Benin, Nigeria.
Courage Ushiobafoh Godday
Department of Biomedical Sciences, Keele University, England, United Kingdom.
Godwin Mmaduabuchi Ikokwu
Faculty of Pharmacy, University of Benin, Nigeria.
Virtue Oniso Okhemukhokho
University of Essex, United Kingdom.
*Author to whom correspondence should be addressed.
According to the World Health Organization (WHO) report in 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, with cases amounting to breast cancer (2.26 million cases), lungs cancer (2.21 million cases), colon and rectum (1.93 million cases), prostate cancer (1.41 million cases) amongst several others. Many cancers can be cured if detected early and treated effectively. At a time like this, the world is in dire need of better and earlier method of cancer detection and diagnosis – this is where cancer theranostic comes in. Cancer theranostics, as the name implies combines cancer diagnosis and cancer therapy with the aim of achieving early diagnosis, accurate molecular imaging, and precise treatment for cancer or tumor cells at the right time and dispensing proper dose of medication, followed by real-time monitoring of treatment efficacy, it aims to improve multi-step procedures and reduce delay in treatment of patients. With the molecular imaging approach in cancer theranostics such as magnetic resonance imaging (mMRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound (US), photoacoustic imaging (PAI), and optical imaging (OI), all of which have overtime been proven to be efficient in the early detection of cancer or tumor cells, and as such help in early treatment and eradication of the disease, it would be right to say that with advances in the precision of identifying biomarkers and imaging and mapping of tumor or cancer cells, cancer treatment in years to come would give an excellent accuracy in diagnosis and treatment, and such treatment would be cheap and affordable.
Keywords: Cancer, theranostics, imaging, biomarkers, nanotheranostics
How to Cite
Embolo Enygue Elisée Libert, Koanga Mogtomo ML, Banai Thomas, Doh Ndeh Gilbert, Tiekwe Eloge, Kojom Foko Loick Pradel, et al. Dynamics of Factors Responsible for the Resurgence of Cervical Cancer Lesions in Women in Developing Countries. J Appl Life Sci Int. 2017;11(2):1–10.
Stamenković M, Knežević A, Knežević I, Kuzmanović I, Karalić D, Milenković S, et al. High-risk human papilloma virus genotypes in cervical carcinoma of Serbian women: Distribution and association with pathohistological findings. Biol J Int Assoc Biol Stand. 2016;44(5):412–416.
Muwonge R, Ngo Mbus L, Ngoma T, Gombe Mbalawa C, Dolo A, da Ganda Manuel M, et al. Socio-demographic and reproductive determinants of cervical neoplasia in seven sub-Sahara African countries. Cancer Causes Control CCC. 2016;27(12):1437–1446.
DeGregorio G, Manga S, Kiyang E, Manjuh F, Bradford L, Cholli P, et al. Implementing a Fee-for-Service Cervical Cancer Screening and Treatment Program in Cameroon: Challenges and Opportunities. The Oncologist; 2017.
Gustafsson L, Sparén P, Gustafsson M, Wilander E, Bergström R, Adami HO. Efficiency of organised and opportunistic cytological screening for cancer in situ of the cervix. Br J Cancer. 1995;72(2):498–505.
Li J, Wang YY, Tian XF, Nan X, Yan T, Wang P, et al. HPV genotype analysis for women in Shaanxi Province of China. Genet Mol Res GMR. 2016;15(4).
Bernard H-U, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers E-M. Classification of Papillomaviruses (PVs) Based on 189 PV Types and Proposal of Taxonomic Amendments. Virology. 2010;401(1):70–79.
Mujuni F, Mirambo MM, Rambau P, Klaus K, Andreas M, Matovelo D, et al. Variability of high risk HPV genotypes among HIV infected women in Mwanza, Tanzania- the need for evaluation of current vaccine effectiveness in developing countries. Infect Agent Cancer. 2016; 11:49.
Sichero L, Picconi MA, Villa LL. The contribution of Latin American research to HPV epidemiology and natural history knowledge. Braz J Med Biol Res. 2020; 53(2):e9560.
Liu Y, Ang Q, Wu H, Xu J, Chen D, Zhao H, et al. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China’s top 3 hospital, 2009–2019. Virol J. 2020;17:104.
de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13.
Martyn F, McAuliffe FM, Wingfield M. The role of the cervix in fertility: is it time for a reappraisal? Hum Reprod. 2014;29(10): 2092–2098.
Kombe AJK, Li B, Zahid A, Mengist HM, Bounda G-A, Zhou Y, et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2020;8.
Chelimo C, Wouldes TA, Cameron LD, Elwood JM. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect. 2013;66(3):207–217.
Irabor DO, Arowolo A, Afolabi AA. Colon and rectal cancer in Ibadan, Nigeria: an update. Colorectal Dis. 2010;12(7Online): e43–e49.
De Vuyst H, Steyaert S, Van Renterghem L, Claeys P, Muchiri L, Sitati S, et al. Distribution of human papillomavirus in a family planning population in nairobi, kenya. Sex Transm Dis. 2003;30(2):137–142.
Si-Mohamed A, Ndjoyi-Mbiguino A, Cuschieri K, Onas IN, Colombet I, Ozouaki F, et al. High prevalence of high-risk oncogenic human papillomaviruses harboring atypical distribution in women of childbearing age living in Libreville, Gabon. J Med Virol. 2005;77(3):430–438.
Kayikcioglu F, Kucukyildiz IA, Gunes M, Özelci R, Dilbaz B, Dilbaz S. Relationship between contraceptive methods and human papillomavirus positivity. Arch Gynecol Obstet. 2020;302(6):1407–1412.